Dyslipidemia in type 2 diabetes mellitus (original) (raw)
Mooradian AD (2003) Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. Arch Intern Med163: 33–40 ArticlePubMed Google Scholar
Gu K et al. (1999) Diabetes and decline in heart disease mortality in US adults. JAMA281: 1291–1299 ArticleCASPubMed Google Scholar
Stamler J et al. (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care16: 434–444 ArticleCASPubMed Google Scholar
Almdal T et al. (2004) The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med164: 1422–1426 ArticlePubMed Google Scholar
Sprafka JM et al. (1991) Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival. The Minnesota Heart Survey. Diabetes Care14: 537–543 ArticleCASPubMed Google Scholar
Haffner SM et al. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior history of myocardial infarction. N Engl J Med339: 229–234 ArticleCASPubMed Google Scholar
Expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA285: 2486–2497
Hachem SB and Mooradian AD (2006) Familial dyslipidaemias: an overview of genetics, pathophysiology and management. Drugs66: 1949–1969 ArticleCASPubMed Google Scholar
Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia46: 733–749 ArticlePubMed Google Scholar
Del Pilar Solano M and Goldberg RB (2005) Management of diabetic dyslipidemia. Endocrinol Metab Clin North. Am34: 1–25 ArticlePubMed Google Scholar
Chahil TJ and Ginsberg HN (2006) Diabetic dyslipidemia. Endocrinol Metab Clin North Am35: 491–510 ArticleCASPubMed Google Scholar
Kannel WB (1985) Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J110: 1100–1107 ArticleCASPubMed Google Scholar
[No authors listed] (1997) U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care20: 1683–1687
Frayn KN (2001) Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc60: 375–380 ArticleCASPubMed Google Scholar
Adiels M et al. (2007) Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia50: 2356–2365 ArticleCASPubMed Google Scholar
Mooradian AD et al. (2007) Low serum high-density lipoprotein cholesterol in obese subjects with normal serum triglycerides: the role of insulin resistance and inflammatory cytokines. Diabetes Obes Metab9: 441–443 ArticleCASPubMed Google Scholar
Mooradian AD et al. (2008) Obesity-related changes in high density lipoprotein metabolism. Obesity16: 1152–1160 ArticleCASPubMed Google Scholar
Mooradian AD et al. (2004) Transcriptional control of apolipoprotein A-I gene expression in diabetes mellitus. Diabetes53: 513–520 ArticleCASPubMed Google Scholar
Beers A et al. (2006) Inhibition of apolipoprotein AI gene expression by tumor necrosis factor α: Roles for MEK/ERK and JNK signaling. Biochemistry45: 2408–2413 ArticleCASPubMed Google Scholar
Dullaart RP et al. (2004) Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest64: 205–215 ArticleCASPubMed Google Scholar
Borggreve SE et al. (2003) Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest33: 1051–1069 ArticleCASPubMed Google Scholar
de Vries R et al. (2005) Plasma cholesteryl ester transfer is a determinant of intima–media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes54: 3554–3559 ArticleCASPubMed Google Scholar
Vergès B et al. (2006) Adiponectin is an important determinant of ApoA-I catabolism. Arterioscler Thromb Vasc Biol26: 1364–1369 ArticlePubMed Google Scholar
Vergeer M et al. (2008) Evaluation of phospholipid transfer protein as a therapeutic target. Future Lipidology3: 327–335 ArticleCAS Google Scholar
Brunzell JD et al. (2008) Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care31: 811–822 ArticleCASPubMed Google Scholar
McQueen MJ et al. (2008) Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case–control study. Lancet372: 224–233 ArticleCASPubMed Google Scholar
Cholesterol Treatment Trialists' (CTT) Collaborators (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomized trials of statins: a meta-analysis. Lancet371: 117–125
Rubins HB et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med341: 410–418 ArticleCASPubMed Google Scholar
Keech A et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet366: 1849–1861 ArticleCASPubMed Google Scholar
Frick MH et al. (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med317: 1237–1245 ArticleCASPubMed Google Scholar
Bantle JP et al. (2008) Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care31 (Suppl 1): S61–S78 CASPubMed Google Scholar
Haffner SM and American Diabetes Association (2004) Dyslipidemia management in adults with diabetes. Diabetes Care27 (Suppl 1): S68–S71 PubMed Google Scholar
Taskinen MR (2002) Controlling lipid levels in diabetes. Acta Diabetol39 (Suppl 2): S29–S34 ArticlePubMed Google Scholar
Krauss RM (2005) Dietary and genetic probes of atherogenic dyslipidemia. Arterioscler Thromb Vasc Biol25: 2265–2272 ArticleCASPubMed Google Scholar
Mensink RP et al. (2003) Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr77: 1146–1155 ArticleCASPubMed Google Scholar
Slyper A et al. (2005) Influence of glycemic load on HDL cholesterol in youth. Am J Clin Nutr81: 376–379 ArticleCASPubMed Google Scholar
Meksawan K et al. (2004) Effect of low and high fat diets on nutrient intakes and selected cardiovascular risk factors in sedentary men and women. J Am Coll Nutr23: 131–140 ArticlePubMed Google Scholar
Mooradian AD et al. (2006) The effect of select nutrients on serum high-density lipoprotein cholesterol and apolipoprotein A-I levels. Endocr Rev27: 2–16 ArticleCASPubMed Google Scholar
Harris WS et al. (1997) Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk4: 385–391 ArticleCASPubMed Google Scholar
Lichtenstein AH (2006) Thematic review series: patient-oriented research. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns. J Lipid Res47: 1661–1667 ArticleCASPubMed Google Scholar
Appel LJ et al. (2005) Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA294: 2455–2464 ArticleCASPubMed Google Scholar
Cheung MC et al. (2001) Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol21: 1320–1326 ArticleCASPubMed Google Scholar
Mooradian AD et al. (2006) Ascorbic acid and alpha-tocopherol down-regulate apolipoprotein A-I gene expression in HepG2 and Caco-2 cell lines. Metabolism55: 159–167 ArticleCASPubMed Google Scholar
Mooradian AD et al. (2001) Obesity: a rational target for managing diabetes mellitus. Growth Horm IGF Res11 (Suppl A): S79–S83 ArticlePubMed Google Scholar
Williams PT (2004) The relationships of vigorous exercise, alcohol, and adiposity to low and high high-density lipoprotein-cholesterol levels. Metabolism53: 700–709 ArticleCASPubMed Google Scholar
Wilund KR et al. (2002) Changes in high-density lipoprotein-cholesterol subfractions with exercise training may be dependent on cholesteryl ester transfer protein (CETP) genotype. Metabolism51: 774–778 ArticleCASPubMed Google Scholar
Halverstadt A et al. (2003) High-density lipoprotein-cholesterol, its subfractions, and responses to exercise training are dependent on endothelial lipase genotype. Metabolism52: 1505–1511 ArticleCASPubMed Google Scholar
Sigal RJ et al. (2007) Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med147: 357–369 ArticlePubMed Google Scholar
Giannopoulou I et al. (2005) Exercise is required for visceral fat loss in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab90: 1511–1518 ArticleCASPubMed Google Scholar
Alam S et al. (2004) The effect of a six-month exercise program on very low-density lipoprotein apolipoprotein B secretion in type 2 diabetes. J Clin Endocrinol Metab89: 688–694 ArticleCASPubMed Google Scholar
Moon YS and Kashyap ML (2004) Pharmacologic treatment of type 2 diabetic dyslipidemia. Pharmacotherapy24: 1692–1713 ArticleCASPubMed Google Scholar
Shepherd J et al. (2005) Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin21: 665–682 ArticleCASPubMed Google Scholar
Roeters van Lennep HW et al. (2008) The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin24: 685–694 ArticleCASPubMed Google Scholar
Constance C et al. (2007) Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes Metab9: 575–584 ArticleCASPubMed Google Scholar
Hildemann SK et al. (2007) Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. Curr Med Res Opin23: 713–719 ArticleCASPubMed Google Scholar
El Harchaoui K et al. (2008) Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins. Am J Cardiovasc Drugs8: 233–242 ArticleCASPubMed Google Scholar
Vergeer M and Kastelein JJ (2008) Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia. Nat Clin Pract Cardiovasc Med5: 302–303 ArticleCASPubMed Google Scholar
Kastelein JJ et al. (2008) Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med358: 1431–1443 ArticleCASPubMed Google Scholar
Cannon CP et al. Vytorin Efficacy International Trial (IMPROVE-IT) Rationale and design of IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J, in press
May HT et al. (2008) Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am J Cardiol101: 486–489 ArticleCASPubMed Google Scholar
Zhao XQ et al. (2004) Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol93: 307–312 ArticleCASPubMed Google Scholar
Ballantyne CM et al. (2008) Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol101: 1428–1436 ArticleCASPubMed Google Scholar
Karas RH et al. (2008) Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs8: 69–81 ArticleCASPubMed Google Scholar
Mooradian AD et al. (2002) The role of thiazolidenediones in the treatment of type 2 diabetes. Treatments in Endocrinology1: 13–20 ArticlePubMed Google Scholar
Howard BV et al. (2008) Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA299: 1678–1689 ArticleCASPubMedPubMed Central Google Scholar
Davidson MH et al. (2005) Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol96: 556–563 ArticlePubMed Google Scholar